Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.

PloS one - 1 Jan 2020

Choi Hye Duck, Chang Min Jung

Abstract excerpt

BACKGROUND: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin rash and diarrhea are well-known and common adverse events in patients receiving erlotinib, whereas other adverse events, including eye, liver, or renal disorders have not been evaluated adequately. This meta-analysis aimed to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Exanthema

Share to Eye Diseases

Share to Gastrointestinal Tract

Share to Kidney Diseases

Source

Open in PubMed Open full text

Identifiers

PMID: 32663210
DOI: 10.1371/journal.pone.0234818
PMCID: PMC7360022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.PMID 32663210Read ↗

Eye, Hepatobiliary, and Renal Disorders of Erlotinib in Patients with Non-Small-Cell Lung Cancer: A Meta-AnalysisSemantic proximity Read ↗

Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.Semantic proximity Read ↗

Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read ↗

Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.Semantic proximity Read ↗

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read ↗

A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.Semantic proximity Read ↗

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Semantic proximity Read ↗

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

[A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].Semantic proximity Read ↗

Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.Semantic proximity Read ↗

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.